BeyondSpring Inc. (BYSI)

BeyondSpring's stock price has experienced fluctuations in the past six months. Key corporate events impacting the stock include the filing of its 2024 Annual Report on Form 10-K with the SEC, which resulted in a mild positive market reaction. Other notable events include earnings reports for Q3 2025, Q2 2025, and Q1 2025, as well as the company's Annual General Meeting on September 15, 2025.

As a clinical-stage biopharmaceutical company, BeyondSpring, Inc. primarily focuses on drug development rather than commercial sales, so traditional demand seasonality does not directly apply. The company's revenue has been minimal or zero in recent years, reflecting its stage of development. Seasonality information available pertains to stock market performance rather than product demand.

BeyondSpring, Inc. is a global, clinical-stage biopharmaceutical company focused on developing and commercializing innovative cancer therapies, particularly in oncology and hematology. The company's lead product is Plinabulin, a first-in-class agent in late-stage clinical development for various indications, including non-small cell lung cancer and chemotherapy-induced neutropenia. BeyondSpring also has research and development capabilities, including immuno-oncology assets and a drug discovery platform.

BeyondSpring is headquartered in New York City, USA, and is actively developing treatments in both China and the United States. The company has a strategic partnership with Hengrui for Plinabulin in Greater China, while retaining 100% of the rights to Plinabulin outside of China.

BeyondSpring has experienced events that could positively influence its brand reputation, including a featured article in Nature by Dr. Grippin and presentations at ESMO Asia and NACLC 2025 on Plinabulin's survival benefits in NSCLC. A human clinical study published in Med (Cell Press) demonstrated Plinabulin-driven dendritic cell maturation and tumor response. Additionally, its subsidiary, Seed Therapeutics, was recognized in Nature review articles and entered a research collaboration with Eisai Co., Ltd.

BeyondSpring Inc. has 31 institutional owners and shareholders who have filed 13D/G or 13F forms with the SEC, collectively holding 6,211,472 shares, representing 40.29% of the stock. Major institutional shareholders include Decheng Capital LLC, Vanguard Group Inc, and BlackRock, Inc. Decheng Capital LLC is a significant shareholder, holding 4,286,104 shares as of September 30, 2025.